Earnings call transcript: McBride H2 2026 profit hit offsets growth plans

McBride reported FY2026 adjusted operating profit of GBP 59 million, down GBP 7.1 million year over year, as a 12.2% two-month surge in raw-material and packaging costs imposed an estimated GBP 6 million Q4 hit. Revenue rose 0.8% nominally but declined 1.8% at constant currency, while EPS fell 0.5 pence; management expects further pricing actions if oil remains at $100-$110 per barrel. Shares rose 1.33% as investors focused on strategic expansion, including the EUR 32.8 million Eurotab acquisition and the Vestacy contract, which is expected to add about GBP 170 million in revenue by H2 FY2028.

Analysis

MCB is transitioning from a cyclical private-label supplier into a scaled European manufacturing platform, but the valuation case now depends on execution rather than a simple inflation pass-through. The Vestacy ramp creates operating leverage from FY28, yet it also raises fixed-cost absorption risk: delayed customer transfers or equipment commissioning would leave MCB carrying project staff, depreciation and higher financing costs before associated volumes arrive. Eurotab offers a nearer-term offset through procurement and network synergies, but its earnings accretion should be tested against integration costs and Turkish FX exposure rather than management’s day-one characterization.

Near term (days to 3 months), the key variable is whether cost recovery catches up before another input move. Private-label demand can support volume, but it does not automatically protect margins when retailers use tendering to retain shelf-price advantage; MCB’s liquids business is most exposed because its inputs are more petrochemical- and packaging-intensive. A sustained easing in oil/feedstock prices would be incrementally positive to margins only after contractual pricing mechanics reset, while a further spike creates another lag and risks FY27 estimate cuts.

The non-obvious upside is strategic: branded household suppliers increasingly have incentive to externalize European production as subscale plants face energy, compliance and automation burdens. Successful Vestacy execution would validate MCB as a preferred consolidator, potentially improving its multiple and creating further pipeline optionality. Conversely, the stock’s recovery leaves little tolerance for a SAP Wave 2 disruption, weak cash conversion during capacity build-out, or net leverage rising faster than EBITDA.

Consensus may be underestimating the value of customer diversification between private label and contract manufacturing, but overestimating the speed at which scale becomes margin. Treat the next two reporting periods as proof points: order ramp, gross-margin recovery, working-capital discipline and unchanged FY28 Vestacy economics matter more than revenue growth.

Key Decisions for Investors

• Maintain/watch MCB rather than chase near highs; initiate only on a pullback or after evidence that H1 FY27 pricing recovers the input-cost gap. Target a 12-18 month position sized for execution risk, with thesis invalidated by a material cut to FY28 Vestacy revenue/margin expectations or net-debt/EBITDA moving above management’s implied comfort range.
• For existing MCB longs, reduce exposure if H1 FY27 adjusted operating margin fails to recover despite price actions, or if working-capital outflows and exceptional spending exceed the planned project profile. The risk is multiple compression from a perceived low-margin contract-manufacturing build rather than balance-sheet distress alone.
• Monitor SAP as a second-order beneficiary only if MCB and comparable European manufacturers demonstrate incremental S/4 deployments translating into measurable productivity. There is no standalone SAP trade from this disclosure; required confirmation is contract backlog, implementation revenue or upgraded FY27 guidance.
• Watch European chemicals/packaging input indicators and Brent: a sustained move above $100/bbl combined with delayed retail pricing is a bearish MCB alert over the next 1-3 months. A durable reversal in feedstock inflation before new price increases are fully embedded would improve cash conversion but may cap the amount of realized pricing upside.